Novartis Oncology Press Releases http://www.novartisoncology.com <![CDATA[Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia]]> 2010-02-19T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1386313&year=2010 <![CDATA[Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer]]> 2010-01-20T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1375090&year=2010 <![CDATA[Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia]]> 2009-12-08T14:30:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1359764&year=2009 <![CDATA[Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting]]> 2009-12-02T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1358558&year=2009 <![CDATA[Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers]]> 2009-11-25T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1357027&year=2009 <![CDATA[Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® as first-line treatment in chronic myeloid leukemia patients]]> 2009-10-20T07:00:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1348449&year=2009 <![CDATA[Results in The New England Journal of Medicine confirm Novartis drug Femara® is superior to tamoxifen after breast cancer surgery]]> 2009-08-19T23:00:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1335978&year=2009 <![CDATA[Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer after failure of targeted therapy]]> 2009-08-06T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1332932&year=2009 <![CDATA[Afinitor® and Sandostatin® LAR® Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months]]> 2009-06-24T17:30:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1324661&year=2009 <![CDATA[Afinitor® Phase II data show positive results for patients with multiple types of lymphoma, leading to Phase III trial]]> 2009-06-08T07:15:00 CET http://www.novartisoncology.com/media/press-releases.jsp?id=1320856&year=2009